Replies to post #210273 on Biotech Values

[DewDiligence]

MAXY continued to incur R&D costs through the JV with Astellas. The gene-shuffling technology was eventually sold to MAXY’s spin-off, CDXS for essentially nothing (#msg-56059056).

[DewDiligence]

Maxygen is still around (as a private company):

https://www.prnewswire.com/news-releases/maxygen-relaunches-in-sunnyvale-to-offer-well-established-molecular-breeding-technology-with-new-collaborative-vision-300601147.html

Maxygen is pleased to announce the availability of the molecular breeding directed evolution platform to the biotechnology industry on a fee-for-service basis. This approach to improving protein function has broad applicability with particular relevance to the fields of synthetic biology, metabolic engineering, gene therapy, immunotherapy, and gene editing.

I thought this technology (such as it is) was owned by CDXS (a spinoff of the original Maxygen) based on the deal announced in 2010 (#msg-56059056).